Penichoux Juliette, Decazes Pierre, Rossi Cédric, Sesques Pierre, Haioun Corinne, Durot Eric, Gower Nicolas, Willaume Alexandre, Oberic Lucie, Paillassa Jérome, Antier Chloé, Renaud Loic, Tournilhac Olivier, Thieblemont Catherine, Besson Caroline, Lebras Laure, Choquet Sylvain, Le Du Katell, Bonnet Christophe, Bailly Sarah, Damaj Ghandi, Laribi Kamel, Houot Roch, Chauchet Adrien, Becker Stéphanie, Tonnelet David, Tilly Hervé, Jardin Fabrice, Lévêque Emilie, Camus Vincent
Department of Hematology and INSERM U1245, Center Henri Becquerel, Rouen, France.
Department of Nuclear Medicine and AIMS, Center Henri Becquerel, Rouen, France.
Hematol Oncol. 2025 Jul;43(4):e70117. doi: 10.1002/hon.70117.
Primary mediastinal large B-cell lymphoma (PMBL) is a rare entity that predominantly affects young female patients and typically presents as a large and compressive anterior mediastinal mass. Accumulating evidence suggests relationships among PMBL patient body composition (BC), cancer outcomes, and treatment-related toxicities. The aim of this study was to evaluate the impact of BC on PMBL patients using PET-CT images acquired pretreatment. Two hundred nineteen patients were included in an ancillary analysis of a multicenter retrospective LYSA cohort of treatment-naïve adult PMBL patients who received first-line treatment with ACVBP, CHOP14 or CHOP21 plus anti-CD20. Anthropometric parameters were assessed from the baseline PET-CT image using two methods: (i) manual segmentation at the L3 level and (ii) automatic software-based multislice measurements with Anthropometer3DNet. The median age was 35.4 years (range 18-88 years), and the median body mass index was 23.8 kg/m (15.6; 40.8). Overall, 137 patients were treated with R-ACVBP, 44 received R-CHOP14, and 38 were treated with R-CHOP21. Patients with low lean body mass had a higher incidence of febrile neutropenia, both in the overall cohort (25% vs. 12.6%, p = 0.02) and in the R-ACVBP subgroup (35.7% vs. 19.4%, p = 0.03). Univariate analysis showed that in patients treated with R-ACVBP, subcutaneous low adiposity, determined by 3D measurements, was associated with overall survival (OS) (p = 0.04). At 3 years, the OS (95% CI) was 96% (93-100) in above-median adiposity patients and 86% (78-95) in below-median adiposity patients. Low lean body mass (LBM), assessed from the pretreatment PET-CT images using automatic Anthropometer3DNet software, may serve as a predictive marker for acute treatment-related toxicity in PMBL patients, particularly those receiving the dose-intensive R-ACVBP regimen. Additionally, depletion of the subcutaneous fat mass was correlated with an increased risk of mortality, highlighting the importance of a comprehensive BC assessment in this patient population.
原发性纵隔大B细胞淋巴瘤(PMBL)是一种罕见的疾病,主要影响年轻女性患者,通常表现为前纵隔的巨大压迫性肿块。越来越多的证据表明,PMBL患者的身体组成(BC)、癌症预后和治疗相关毒性之间存在关联。本研究的目的是使用治疗前采集的PET-CT图像评估BC对PMBL患者的影响。219例患者纳入了一项多中心回顾性LYSA队列的辅助分析,该队列中的初治成年PMBL患者接受了ACVBP、CHOP14或CHOP21加抗CD20的一线治疗。使用两种方法从基线PET-CT图像评估人体测量参数:(i)L3水平的手动分割,以及(ii)使用Anthropometer3DNet基于软件的自动多层测量。中位年龄为35.4岁(范围18-88岁),中位体重指数为23.8kg/m²(15.6;40.8)。总体而言,137例患者接受了R-ACVBP治疗,44例接受了R-CHOP14治疗,38例接受了R-CHOP21治疗。低瘦体重患者发热性中性粒细胞减少的发生率更高,在整个队列中(25%对12.6%,p=0.02)以及在R-ACVBP亚组中(35.7%对19.4%,p=0.03)均如此。单因素分析显示,在接受R-ACVBP治疗的患者中,通过三维测量确定的皮下低脂肪与总生存期(OS)相关(p=0.04)。3年时,脂肪量高于中位数的患者的OS(95%CI)为96%(93-100),脂肪量低于中位数的患者为86%(78-95)。使用自动Anthropometer3DNet软件从治疗前PET-CT图像评估的低瘦体重(LBM),可能作为PMBL患者急性治疗相关毒性的预测标志物,特别是那些接受剂量密集型R-ACVBP方案的患者。此外,皮下脂肪量的减少与死亡风险增加相关,突出了在该患者群体中进行全面BC评估的重要性。